Biotechnology

TransCode Therapeutics

TransCode Therapeutics released FY2025 Q3 earnings on November 14, 2025 (EST) with actual revenue of USD 0 and EPS of USD -5.8248

TransCode Therapeutics released FY2025 9 Months Earnings on November 14, 2025 (EST) with actual revenue of USD 0 and EPS of USD -81.1122

TransCode Therapeutics released FY2025 Q2 earnings on August 14 (EST) with actual revenue of USD 0 and EPS of USD -5.1298

TransCode Therapeutics released FY2025 Semi-Annual Earnings on August 14 (EST), actual revenue USD 0, actual EPS USD -32.4478

TransCode Therapeutics released FY2025 Q1 earnings on May 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -70.1575 (forecast USD --)

TransCode Therapeutics' Cancer Treatment Drug TTX-MC138 Phase 1a Initial Dosing Successfully Completed

TransCode Therapeutics Inc. Seeks Hearing to Address Delisting Risk

TransCode Therapeutics Announces Reverse Split

TransCode Therapeutics Announces Positive Progress in TTX-MC138 Phase 1a Clinical Trial

TransCode Therapeutics released FY2024 Q4 earnings on April 15 (EST), actual revenue USD 0 (forecast USD 300K), actual EPS USD -271.5735

TransCode Therapeutics released FY2024 earnings on April 15 (EST), actual revenue USD 0 (forecast USD 300K), actual EPS USD -1.317K

TransCode Therapeutics Announces Sale of 10.25 Million Shares of Common Stock and Warrants

TransCode Therapeutics, Inc. Shareholders Approve Proposals for Series C and D Warrants

TransCode Therapeutics released FY2024 9 Months Earnings on November 14 (EST) with actual revenue of USD 0 and EPS of USD -146.0634

TransCode Therapeutics released FY2024 Q3 earnings on November 14 (EST), actual revenue USD 0 (forecast USD 300K), actual EPS USD -146.0634

TransCode Therapeutics Launches Phase 1 Clinical Trial

TransCode Therapeutics released FY2024 Semi-Annual earnings on August 14, 2024 (EST) with actual revenue of USD 0 and EPS of USD 0

TransCode Therapeutics released FY2024 Q2 earnings on August 14, 2024 (EST) with actual revenue of USD 0 and EPS of USD 0.

Transcode Therapeutics Inc Announces Proposed Public Offering of Common Stock

TransCode Therapeutics, Inc. announces significant progress

AdvisorShares MSOS 2x Daily ETF

cbdMD

Tryhard

Roundhill Cannabis ETF

Neo-Concept

Amplify Seymour Cannabis ETF

AdvisorShares Pure US Cannabis ETF

Canopy Growth

RYTHM

Tilray Brands

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap